CSIMarket
 


Cryoport inc   (CYRX)
Other Ticker:  
 

Cryoport Inc 's Tangible Leverage Ratio

CYRX's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


Due to net new borrowings of 1.21%, Tangible Leverage Ratio fell to 2.52, above the Cryoport Inc 's average Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 101 other companies have achieved lower Tangible Leverage Ratio than Cryoport Inc in the IV Quarter 2023. While Tangible Leverage Ratio total ranking has improved so far in the forth quarter 2023 to 1001, from total ranking in the third quarter 2023 at 1148 .

Explain Tangible Leverage Ratio?
What is CYRX Market Share?
What are CYRX´s Total Liabilities?


CYRX Tangible Leverage Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Tangible Equity Change -12.86 % -9.49 % -12 % -16.78 % -27.17 %
Y / Y Total Liabilities Change -2.07 % -2.38 % 2.52 % 4.21 % 2.49 %
Tangible Leverage Ratio MRQ 2.52 2.37 2.43 2.21 2.24
CYRX's Total Ranking # 1001 # 1148 # 1629 # 1664 # 790
Seq. Tangible Equity Change -4.79 % -2.17 % -9.41 % 3.28 % -1.12 %
Seq. Total Liabilities Change 1.21 % -4.78 % -0.25 % 1.87 % 0.89 %



Tangible Leverage Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 102
Healthcare Sector # 236
Overall Market # 1001


Tangible Leverage Ratio Statistics
High Average Low
5.8 0.71 0.07
(Dec 31 2011)   (Dec 31 2019)




Financial Statements
Cryoport Inc 's Tangible Equity $ 186 Millions Visit CYRX's Balance sheet
Cryoport Inc 's Total Liabilities $ 469 Millions Visit CYRX's Balance sheet
Source of CYRX's Sales Visit CYRX's Sales by Geography


Cumulative Cryoport Inc 's Tangible Leverage Ratio

CYRX's Tangible Leverage Ratio for the trailling 12 Months

CYRX Tangible Leverage Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Tangible Equity TTM Growth -12.86 % -9.49 % -12 % -16.78 % -27.17 %
Y / Y Total Liabilities TTM Growth -2.07 % -2.38 % 2.52 % 4.21 % 2.49 %
Tangible Leverage Ratio TTM 2.37 2.31 2.27 2.18 2.06
Total Ranking TTM # 849 # 8 # 1553 # 6 # 699
Seq. Tangible Equity TTM Growth -4.79 % -2.17 % -9.41 % 3.28 % -1.12 %
Seq. Total Liabilities TTM Growth 1.21 % -4.78 % -0.25 % 1.87 % 0.89 %


On the trailing twelve months basis Due to the net new borrowings of 1.21% during the trailing twelve months finishing in the IV Quarter 2023, cumulativeTangible Leverage Ratio improved to 2.37, above the Cryoport Inc 's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 86, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Cryoport Inc . While Tangible Leverage Ratio total ranking has deteriorated during the twelve months ending in the IV Quarter 2023, compared to the prior period, from 8 to 849.

Explain Tangible Leverage Ratio?
What is CYRX Market Share?
What are CYRX´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 87
Healthcare Sector # 214
Within the Market # 849


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
1.41 0.48 0.12
(Sep. 30, 2015)   (Sep 30 2018)




Companies with similar Tangible Leverage Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioDec 31 2023 MRQ Total LiabilitiesDec 31 2023 MRQ Tangible Equity
Ionis Pharmaceuticals Inc  6.73 $ 2,603.386  Millions$ 386.686  Millions
Bio path Holdings inc   6.30 $ 2.779  Millions$ 0.441  Millions
Travere Therapeutics Inc   6.10 $ 588.103  Millions$ 96.367  Millions
Assertio Holdings inc   5.56 $ 148.416  Millions$ 26.671  Millions
Mersana Therapeutics Inc   5.13 $ 189.156  Millions$ 36.904  Millions
Gossamer Bio Inc   3.97 $ 249.147  Millions$ 62.769  Millions
Phibro Animal Health Corporation  3.79 $ 626.625  Millions$ 165.158  Millions
Perrigo Company Plc  3.14 $ 5,615.400  Millions$ 1,787.100  Millions
Arcutis Biotherapeutics Inc   3.07 $ 252.698  Millions$ 82.229  Millions
Clene Inc   2.91 $ 38.951  Millions$ 13.390  Millions
Soligenix inc   2.84 $ 7.153  Millions$ 2.522  Millions
Cryoport inc   2.52 $ 468.721  Millions$ 186.238  Millions
G1 Therapeutics Inc   2.43 $ 86.154  Millions$ 35.386  Millions
Ani Pharmaceuticals Inc  2.41 $ 471.673  Millions$ 195.519  Millions
Proqr Therapeutics N v   2.33 $ 108.072  Millions$ 46.357  Millions
Novartis Ag  2.27 $ 53,195.000  Millions$ 23,409.000  Millions
Biovie Inc   2.11 $ 13.981  Millions$ 6.623  Millions
Liquidia Corporation  1.78 $ 71.039  Millions$ 39.960  Millions
Summit Therapeutics Inc   1.65 $ 125.257  Millions$ 75.799  Millions
Xoma Corporation  1.64 $ 145.580  Millions$ 88.721  Millions
Ocular Therapeutix Inc   1.54 $ 139.916  Millions$ 91.131  Millions
Eton Pharmaceuticals Inc   1.51 $ 16.263  Millions$ 10.738  Millions
Lifevantage Corp  1.31 $ 35.375  Millions$ 26.918  Millions
2seventy Bio Inc   1.25 $ 310.126  Millions$ 248.706  Millions
Verastem inc   1.24 $ 71.185  Millions$ 57.374  Millions
23andme Holding Co  1.22 $ 231.023  Millions$ 189.010  Millions
Cara Therapeutics inc   1.20 $ 68.759  Millions$ 57.085  Millions
Talphera Inc   1.19 $ 6.290  Millions$ 5.286  Millions
Sonoma Pharmaceuticals Inc   1.18 $ 7.926  Millions$ 6.692  Millions
Sonnet Biotherapeutics Holdings Inc   1.07 $ 2.765  Millions$ 2.572  Millions

Date modified: 2024-03-13T23:04:03+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com